Lindus Health and Quotient Sciences have announced a strategic partnership aimed at enhancing patient recruitment for Phase I-IIa clinical studies, facilitating a seamless transition from first-in-human (FIH) trials to proof-of-concept (POC) stages. This collaboration directly addresses the inefficiencies often encountered in the drug development process, where companies typically engage multiple vendors across various phases, leading to operational delays.
The partnership leverages Quotient’s expertise in early clinical and drug development with Lindus’ proven capabilities in patient recruitment and trial delivery. This integration promises a more cohesive development continuum, allowing sponsors to focus on advancing their scientific endeavors rather than managing multiple vendors. With Quotient Sciences conducting over 70 Phase I studies annually and Lindus Health providing comprehensive recruitment support, the collaboration is positioned to significantly accelerate trial timelines and improve enrollment rates.
As the demand for specific patient cohorts in early-phase studies increases, this partnership is crucial in streamlining clinical development processes. By reducing administrative burdens and eliminating the need for separate Phase I and later-stage CROs, Lindus and Quotient aim to enhance the efficiency of drug development, ultimately expediting the delivery of innovative treatments to patients.
Get started today with Solo access →
